Vice President

Progyny CEO Pete Anevski outlined the company's utilization forecasting and the rollout of its fully insured product, Progyny Select, during a KeyBanc conference. He said the company focuses on actual benefit use rather than eligible lives counts, noting utilization has remained stable at approximately 1.03% to 1.09%. Anevski explained that Q1 consultations typically drive higher-revenue treatment activity in Q2 through Q4. The company forecasts using client history, industry patterns and where members are in their fertility journey. Progyny Select will target small-group employers through brokers and professional employer organisations, covering IVF only with lifetime caps and annual repricing to manage risk. Commercialisation begins now, but the product is expected to go live in 2027. Anevski said recent selling seasons showed no increased competition, with Progyny continuing to win "the majority of the time" against competitors.

Progyny to participate in inaugural HHS Women's Health conference. Company's Chief Medical Officer to present new fertility research that shows value of personalized care and treatment guidance for improving outcomes NEW YORK, March 11, 2026 - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that Chief Medical Officer Janet Choi, MD, will present new fertility research during the first annual Health and Human Services (HHS) National Conference on Women's Health, March 11-13, 2026, in Washington, DC. The event will bring together leaders across the industry to explore breakthroughs in research, prevention, diagnosis, and treatment of health conditions that affect women across the lifespan. Progyny's participation in the conference represents the company's role in contributing to and helping shape the national conversation on advancing women's health. As a recognized leader in fertility, family building, and women's health benefits, Progyny has spent the past decade partnering with employers, health plans, and clinical leaders to elevate the standard of care, improve outcomes for women and families, and advance innovation. The company has one of the largest data sets on fertility in the U.S., providing a unique ability to gather insights that can improve health outcomes. The fertility research being presented, co-authored by Alan Copperman, MD, Managing Director and CEO of RMA of New York, assessed how integrated education and clinician-guided decision-making influence treatment selection, timing, clinical outcomes, and cost of care. Key findings include: * Early cycle awareness can support informed decision-making: Nearly half of women who received early cycle-aware education did not pursue fertility treatment. * Personalized fertility care can help patients reach pregnancy more efficiently, limiting the emotional and physical toll: In this member population - where benefit design did not mandate step-protocol requirements - time to achieve a successful pregnancy in days was up to 42% shorter. * Age remains an important factor in fertility treatment success: In this analysis, only approximately 8% of IUI (intrauterine insemination) cycles were successful among patients age 35 and over, reinforcing the importance of timely evaluation and individualized care planning. * Individualized treatment decisions may help optimize birth outcomes and cost: Treatment pathways should consider the risk of multiples which can increase the likelihood of neonatal intensive care needs and associated costs. "Fertility care is highly personal and time-sensitive, and treatment decisions should reflect each patient's clinical circumstances. These findings underscore the value of personalized, clinician-guided care in helping patients make informed decisions about their family building journey," said Janet Choi, MD, Chief Medical Officer, Progyny. "The selection of Progyny's fertility research for presentation at this national forum highlights the relevance of evaluating how fertility care pathways affect patient experience and outcomes." About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. Progyny Inc. envision a world where everyone can realize their dreams of family and ideal health. Its outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Its benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com. For Further Information, Please Contact: